Clinical and Financial Case Study
BioSherpa™ STS grew Klebsiella oxytoca despite 3 days of effective antibiotics. Control grew only normal flora.
BioSherpa™ STS provided a more accurate diagnosis that resulted in:
A de-escalation of antibiotic treatment to the patient, avoiding significant side effects and cost.
An increase in hospital Case Mix Index due to diagnostic specificity.
An economic benefit to the hospital of almost $1,800 resulting from a cost savings of almost $1,000 by using a more targeted antibiotic and an increased reimbursement to the hospital of almost $800 due to allowances for enhanced diagnostic specificity.
More accurate data that will easily interface with advanced electronic medical record charge capture platforms such as Epic.